Acurx Pharmaceuticals (NASDAQ:ACXP) Posts Earnings Results, Beats Estimates By $0.70 EPS

Acurx Pharmaceuticals (NASDAQ:ACXP) released its quarterly earnings data on Thursday. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($1.01) by $0.70, Zacks reports.

Acurx Pharmaceuticals Price Performance

ACXP opened at $3.88 on Friday. The firm has a market capitalization of $9.89 million, a PE ratio of -0.69 and a beta of -1.16. The business’s 50-day moving average is $2.39 and its two-hundred day moving average is $3.82. Acurx Pharmaceuticals has a 1 year low of $1.33 and a 1 year high of $21.00.

Institutional Trading of Acurx Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Armistice Capital LLC bought a new position in shares of Acurx Pharmaceuticals during the 2nd quarter worth approximately $551,000. Millennium Management LLC acquired a new stake in Acurx Pharmaceuticals in the fourth quarter valued at approximately $103,000. Geode Capital Management LLC purchased a new position in Acurx Pharmaceuticals in the fourth quarter worth $31,000. Finally, Jane Street Group LLC acquired a new position in shares of Acurx Pharmaceuticals during the fourth quarter worth $27,000. 11.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on ACXP. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Wednesday, January 21st. Wall Street Zen raised shares of Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, December 28th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $31.00.

More Acurx Pharmaceuticals News

Here are the key news stories impacting Acurx Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat expectations and company update: Acurx reported Q4 2025 results that topped consensus (EPS -$0.31 vs. -$1.01 est.) and issued a business update noting a stronger cash position and clinical progress, which is supportive fundamental news. Press Release
• Positive Sentiment: Conference call and transcript available: Management held an earnings call (transcript available) that investors can review for pipeline timing, cash runway and next clinical milestones—important details for biotech valuation. Earnings Call Transcript
• Neutral Sentiment: Media coverage and listings: Multiple outlets published summaries and coverage of the quarter and company update (useful for market context). MSN Article
• Neutral Sentiment: Short interest data appears anomalous: Reports in the feed show a large increase in short interest but list zero shares and NaN changes — data looks unreliable and should be treated cautiously until confirmed by an exchange report.
• Negative Sentiment: Analyst projections of continued losses: HC Wainwright published quarterly estimates showing continued negative EPS across 2026 (Q1 -$0.59, Q2 -$0.63, Q3 -$0.70, Q4 -$0.75 and full-year consensus ~ -$0.89), reinforcing that Acurx remains a loss-making, development-stage biotech and likely to need additional funding—this raises dilution and execution risk.
• Negative Sentiment: Market reaction likely reflects risk/reward tradeoff: Despite the Q4 beat, investors often focus on forward cash burn, clinical timelines and financing needs for small-cap biotechs; HC Wainwright’s continued negative EPS outlook and uncertainty about future funding likely pressured the share price today.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).